Page last updated: 2024-08-24

topotecan and paclitaxel

topotecan has been researched along with paclitaxel in 311 studies

Research

Studies (311)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's49 (15.76)18.2507
2000's163 (52.41)29.6817
2010's87 (27.97)24.3611
2020's12 (3.86)2.80

Authors

AuthorsStudies
Gibbons, S; Kaatz, GW; Zloh, M1
Collett, A; Hallifax, D; Tanianis-Hughes, J; Warhurst, G1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L1
Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M1
Chen, X; Lin, X; Skolnik, S; Wang, J1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Goto, M; Lee, KH; Li, SG; Liu, YQ; Morris-Natschke, SL; Song, ZL; Wu, D; Wu, XB; Yang, L; Zhao, XB; Zhao, Y; Zhu, GX1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Fu, ZD; Huang, JT; Ji, TF; Li, DZ; Li, XY; Lin, JP; Liu, HY; Pan, XD; Song, HX; Wang, CY; Zhang, QZ; Zhang, YL1
Bi, C; Deng, H; Fan, T; Shao, R; Song, D; Wang, Y; Yang, P; Ye, C; Zhang, N1
Jing, Y; Ojima, I; Wang, C; Wang, X1
Culine, S; Extra, JM; Giacchetti, S; Madelaine, I; Marty, M; Rousseau, F1
Erlichman, C1
Slichenmyer, WJ; Von Hoff, DD1
Brewster, L; Green, MR; Hargis, JB; Hollis, DR; Lilenbaum, RC; Miller, AA; O'Brien, SM; Ratain, MJ; Rosner, GL; Schilsky, RL1
Ettinger, DS1
Cheson, B; Christian, M; Feigal, EG; Friedman, MA; Grever, M1
Grant, SC; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR1
Bosl, GJ; Chou, TC; Motzer, RJ; Tong, Y1
Green, MR1
Chantarawiroj, P; Edwards, CL; Freedman, RS; Gonzalez de Leon, C; Hord, M; Kavanagh, JJ; Kim, EE; Kudelka, AP; Levenback, C; Madden, T; Raber, M; Tresukosol, D; Verschraegen, C; Wallin, B1
Fields, AL; Goldberg, GL; Runowicz, CD1
Green, MR; Lilenbaum, RC; Lynch, TJ; Miller, AA; Ratain, MJ; Rosner, GL; Schilsky, RL1
Catimel, G; Talon, A1
Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D1
Mani, S; Ratain, MJ1
Alvarez, RD; Armstrong, DK; Barker, SD; Bookman, MA; Fleming, GF; Horowitz, IR; McGuire, WP; O'Reilly, S; Ozols, RF; Rowinsky, EK; Schilder, RJ; Walczak, JR1
Christensen, IJ; Holm, B; Jensen, PB; Sehested, M; Sorensen, M1
Tannock, IF; Vukovic, V1
Armstrong, D; Carmichael, J; Gordon, A; Malfetano, J; ten Bokkel Huinink, W1
Dunton, CJ1
Bolis, G; Broom, C; Carmichael, J; Coleman, R; Davidson, N; Fields, SC; Gordon, A; Gore, M; Heron, JF; Hudson, I; Malfetano, J; Malmström, H; Scarabelli, C; Spanczynski, M; ten Bokkel Huinink, W1
Elbendary, A; Herzog, TJ; Mutch, DG; Rader, JS; Swisher, EM1
Ozols, RF1
Furuse, K1
Sugiyama, T; Ushijima, K; Yakushiji, M1
Negoro, S2
Kaufmann, SH; Rowinsky, EK1
Ghaemmaghami, M; Jett, JR1
Fueyo, J; Gomez-Manzano, C; Kyritsis, AP; Levin, VA; Martin-Duque, P; Perez-Soler, R; Puduvalli, VK; Yung, WK1
Bunn, PA; Kelly, K1
Ansari, R; Bitran, JD; Fasanmade, AA; Fleming, GF; Hoffman, PC; Klepsch, A; Kugler, JW; Malone, D; Ratain, MJ; Vokes, EE1
Carney, DN1
de Jonge, MJ; Sparreboom, A; Verweij, J1
Bolis, G; Bookman, MA; Fields, SZ; Gordon, A; Krebs, JB; Lissoni, A; Malmström, H1
Cannistra, SA1
Beijnen, JH; Beusenberg, FD; Doyle, E; Hearn, S; Herben, VM; Panday, VR; Richel, DJ; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van der Vange, N1
Burris, HA; Greco, FA; Hainsworth, JD; Morrissey, LH1
Bleuzen, P; Buthaud, X; Cvitkovic, E; Goldwasser, F; Gross, M; Jasmin, C; Misset, JL; Romain, D; Voinea, A1
Apicella, A; Cartení, G; Comella, G; Comella, P; Frasci, G; Gravina, A; Guida, T; Lapenta, L; Lombardi, R; Natale, M; Nicolella, GP; Pacilio, C; Panza, N1
Howell, SB; Lin, X1
Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P1
Khattab, J; Urba, SG1
Chakravarthy, A; Choy, H; Johnson, D1
Ghamande, SA; Piver, MS1
Cesano, A; Fields, SZ; Lane, SR; Poulin, R; Ross, G1
Bartussek, C; Naumann, U; Weller, M1
Cabanillas, F1
Ferreira, CG; Giaccone, G; Kummer, AJ; Peters, GJ; Pinedo, HM; Span, SW; Tolis, C; van Lopik, T1
Atassi, G; Guilbaud, N; Jan, M; Kraus-Berthier, L; Naze, M; Pierré, A1
Boisdron-Celle, M; Boulanger, N; Gamelin, E1
Bianco, AR; Caputo, R; Ciardiello, F; De Laurentiis, M; De Placido, S; Pomatico, G; Tortora, G1
Lu, H; Nair, RV; Seiden, MV; Supko, JG1
Cacciari, N; Martoni, A; Zamagni, C1
Kelly, K2
Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Pomatico, G; Tortora, G1
Abad, A; Guillot, M; Martin, C; Plasencia, C; Taron, M1
Ferguson, MJ; Rankin, EM1
Fluellen, L; Fusco, N; Gordon, NH; Hoppel, CL; Ingalls, ST; Rodriguez, M; Rose, PG1
Sandler, A1
Brooks, SE; Day, RS; Dobson, JM; Doyle, LA; Egorin, MJ; Meisenberg, BR; Nemieboka, NN; Tait, NS; Tkaczuk, KH; Van Echo, DA; Zamboni, WC1
Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K1
Eckhardt, SG; Hammond, LA; Hilsenbeck, SG; MacDonald, JR; Mangold, G; Marty, J; Rowinsky, EK; Von Hoff, DD; Weitman, S1
Dubuc-Lissoir, J; Eisenhauer, E; Fisher, B; Grimshaw, R; Hoskins, P; Oza, A; Plante, M; Stuart, G; Vergote, I; Vermorken, J1
Bolis, G; Mangili, G; Parazzini, F; Scarfone, G; Tateo, S; Villa, A1
Doyle, LA; Edelman, MJ; Egorin, MJ; Hausner, PF; Meisenberg, BR; Tait, NS; Tkaczuk, KH; Van Echo, DA; Zamboni, WC1
Amo-Takyi, BK; Boabang, P; Kohlhagen, H; Kurbacher, CM; Waida, A1
D'Agostino, G; Ferrandina, G; Greggi, S; Lorusso, D; Mancuso, S; Manzione, L; Salerno, MG; Scambia, G1
Adams, AL; Boente, M; Bookman, MA; Ciccotto, S; Gallo, JM; Millenson, MM; Ozols, RF; Padavic-Shallers, K; Rogatko, A; Rogers, B; Rosenblum, N; Schilder, RJ; Weiner, LM1
Bolis, G; Carmichael, J; Coleman, R; Davidson, N; Fields, SZ; Gordon, A; Gore, M; Héron, JF; Malfetano, J; Malmström, H; Ross, G; Scarabelli, C; Spaczynski, M; ten Bokkel Huinink, W; Vennin, P1
Malik, IA1
Dingemans, AC; Giaccone, G; Postmus, PE; Scagliotti, GV; Span, S; van Ark-Otte, J; van der Valk, P1
Allen, D; Davison, J; Gates, P; Neesham, D; Planner, R; Prince, HM; Quinn, M; Rischin, D1
Bolis, G; Parazzini, F; Scarfone, G; Villa, A1
Brunetti, C; Carreca, I; Comella, G; Comella, P; DeCataldis, G; Frasci, G; Muci, D; Natale, M; Nicolella, G; Palmeri, S; Panza, N; Piantedosi, F; Russo, A1
Avula, R; Bible, KC; Hartmann, LC; Huang, H; Kalli, K; Kaufmann, SH; Lee, YK; Shridhar, V; Smith, DI; Staub, J1
Cantrell, CL; Dunleavy, TL; Dunphy, FR; Harrison, BR; Petruska, PJ; Pincus, SM; Richart, JM; Visconti, JL1
Agrawal, S; Bianco, AR; Borriello, G; Caputo, R; Ciardiello, F; Kandimalla, ER; Mendelsohn, J; Tortora, G; Troiani, T1
Gerçel-Taylor, C; Manahan, KJ; Taylor, DD1
Burris, HA; Greco, FA; Hainsworth, JD1
Bookman, MA4
Cabanillas, F; Hagemeister, FB; McLaughlin, P; Palmer, JL; Preti, HA; Rodriguez, MA; Romaguera, JE; Samuels, BI; Younes, A1
Berkowitz, RS; Campos, SM; Cook, S; Fuller, AF; Goodman, A; MacNeill, KM; Matulonis, UA; Penson, RT; Seiden, MV; Supko, JG1
Bahadori, HR; Catapano, CV; Green, MR1
Eckardt, JR1
Cliby, WA; Kaufmann, SH; Lewis, KA; Lilly, KK1
Hassan, SB; Jonsson, E; Karlsson, MO; Larsson, R1
du Bois, A1
Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S1
Thigpen, T1
Leslie, KK1
Kato, Y; Saijo, N1
Bobiak, ML; Chaturvedi, P; Fisher, PW; Hurle, MR; Jablonski, SA; Mattern, MR; Sudakin, V; Yen, TJ; Zhou, BB; Zhu, Y1
Beijnen, JH; de Jong, LA; Herben, VM; Pluim, D; Schellens, JH; Schoemaker, NE; ten Bokkel Huinink, WW; van Waardenburg, RC1
Doherty, MG; Gordon, AN; Hancock, KC; Matthews, CM; Messing, M; Stringer, CA; Teneriello, M1
Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C2
Aguilar-Cordova, E; Engehausen, DG; Fischer, DC; Kieback, DG; Oehler, MK; Sauerbrei, W; Tong, XW1
Duan, Z; Kronish, KM; Lamendola, DE; Penson, RT; Seiden, MV1
Burris, HA; Gray, JR; Greco, FA; Hainsworth, JD; Houston, GA; Morrissey, LH; Prasthofer, EF; Scullin, DC1
Hensley, ML1
Allott, CP; Boxall, FE; Kelland, LR; Rogers, P; Stephens, TC1
Herzog, TJ2
D'Orazio, A; Gibson, AD1
Gutierrez, M; Lhomme, C; Pautier, P1
Ash-Bernal, R; Browner, I; Erlich, R1
Benigno, B; Homesley, H; Vaccarello, L; Williams, J1
Bonnar, J; Gleeson, NC; McGuinness, EP; O'Toole, SA; Sheppard, BL; Yoneda, M1
Birch, R; Campos, L; Hainsworth, J; Schnell, F; Tongol, J; West, W1
Inciūra, A; Juozaityte, E1
Fields, AL; Runowicz, CD1
Dropcho, S; Fife, K; Hanna, N; Seitz, DE; Sweeney, C1
Gabryś, M; Gerber, J; Goluda, M; Jedryka, M1
Bauman, MD; Hatfield, AK; Hillman, S; Jett, JR; Kugler, JW; Levitt, R; Mailliard, JA; Marks, RS; Morton, RF1
Coldman, BJ; Fossella, FV; Glisson, BS; Komaki, R; Kurie, JM; Lee, JS; Lu, C; Palmer, JL; Pisters, KM; Shin, DM1
Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D2
Balat, O; Ugur, MG1
Ardizzoni, A; de Cupis, A; Favoni, RE; Loprevite, M; Pirani, P; Semino, C1
Bookman, M; Copeland, LJ; Trimble, E1
Fiorica, JV1
Herzog, TJ; Holloway, RW; Stuart, GC1
Baselga, J; Carrato, A; Domine, M; Felip, E; Font, A; Garrido, P; Mañe, JM; Rosell, R; Santomé, L; Terrasa, J; Vadell, C1
Bukowski, R; Canetta, R; Ganapathi, R; Grabowski, D; Lee, F; Markman, M; Mekhail, T; Peck, R; Takigawa, N; Uyar, D1
Greco, FA1
Dowlati, A; Levitan, N1
Lane, SR; Ross, GA; ten Bokkel Huinink, W1
Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C; Høgdall, EV1
Belani, CP; Day, R; Jacobs, SA; Jett, JR; Ramalingam, S; Zamboni, BA1
Brafman, LB; Hershman, DL; Resnik, EE; Selleck, MJ; Shriberg, L; Smith, D; Tiersten, AD; Troxel, AB1
Agarwal, R; Foster, T; Guppy, AE; Nelstrop, AE; Rustin, GJ; Seckl, MJ1
Ali, K; Fung, MF; Hopkins, L; Le, T; Leis, A; Pahwa, P; Reeder, B; Wright, K1
Pfisterer, J1
Aghajanian, C; Ben-Porat, L; Chi, DS; Hensley, ML; Hoppe, B; Prasad, M; Sabbatini, P1
Hayakawa, Y1
Christodoulou, C; Deliyiannis, F; Malamos, NA; Rigatos, SK; Skarlos, DV; Stathopoulos, GP; Stathopoulos, JG1
Bogart, JA; Green, MR; Herndon, JE; Lee, ME; Lyss, AP; Miller, AA; Turrisi, AT; Watson, D1
Catapano, CV; Freeman, KD; Green, MR; Mushtaq, C; Oakhill, G; Pacheco, D; Rocha Lima, CM; Sherman, CA1
Biamonte, R; Cartenì, G; Danese, S; De Laurentiis, M; De Matteis, A; De Placido, S; Di Vagno, G; Febbraro, A; Gallo, C; Gasparini, G; Greggi, S; Lauria, R; Lombardi, AV; Manzione, L; Marinaccio, M; Naglieri, E; Perrone, F; Pignata, S; Scambia, G; Valerio, MR1
Gibb, RK; Herzog, TJ; Horowitz, NS; Hua, J; Mutch, DG1
Haller, G; Horak, P; Krainer, M; Pils, D; Pribill, I; Rössler, M; Tomek, S; Zielinski, CC1
Christensen, IJ; Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C1
Asmar, L; Bailey, CL; Gordon, AN; Messing, MJ; Pippitt, CH; Savage, J; Street, DG; Young, JA1
Apolone, G; Buda, A1
Castleberry, R; Joshi, V; Kletzel, M; Kretschmar, CS; London, WB; Marcus, R; Murray, K; Smith, EI; Thorner, P1
Johnston, SR1
Casas, F; Jeremic, B1
Baki, M; Bodoky, G; Cseh, J; Csejtei, A; Csömör, S; Dank, M; Erfán, J; Esik, O; Faluhelyi, Z; Hernádi, Z; Izsó, J; Kammerer, K; Kásler, M; Krommer, K; Magyar, T; Mayer, A; Megyery, E; Moskovits, K; Pécsi, L; Pikó, B; Pintér, T; Pulay, T; Ruzsa, A; Szánthó, A; Szántó, I; Szántó, J; Szucs, M; Tálos, Z; Thurzó, L1
Choi, M; Fogoros, S; Griffith, KA; Hu, YY; Liu, JR; Lucas, PC; Williams, J1
Cromwell, LD; Fadul, CE; Kingman, LS; McDonnell, CE; Meyer, LP; Pipas, JM; Rhodes, CH; Rigas, JR1
Beijnen, JH; Bos, AM; De Vos, FY; de Vries, EG; Gietema, JA; Mourits, MJ; Rosing, H; van der Zee, AG; Willemse, PH1
Altundag, K; Altundag, O; Gunduz, M; Morandi, P1
Berman, ML; Burger, RA; Disaia, PJ; Fruehauf, JP; Kyshtoobayeva, AS; Manetta, A; Mehta, RS; Monk, BJ; Tewari, KS; Yu, IR1
Kegel, T; Mueller, T; Schmoll, HJ; Simon, H; Voigt, W; Weiss, M1
Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C1
Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC1
Burges, A; du Bois, A; Gropp, M; Harter, P; Huober, J; Pfisterer, J; Schade-Brittinger, C; Schmalfeldt, B; Staehle, A; Wollschlaeger, K1
Antoniou, D; Armenaki, O; Athanasiadis, A; Christodoulou, Ch; Dimitroulis, J; Georgatou, N; Giamboudakis, P; Giannakakis, T; Katis, K; Rigatos, SK; Skarlos, D; Stathopoulos, GP; Stathopoulos, J1
Duska, L; He, X; Klein, A; Mallett, A; Roche, M; Seiden, MV; Supko, JG1
Burris, HA; Corso, SW; Erland, JB; Greco, FA; Hainsworth, JD; Joseph, G; Morrissey, LH; Spigel, DR; Spremulli, E; Thompson, DS1
Belinson, JL; Michener, CM1
Fayad, L; Goy, A; Hagemeister, FB; Loyer, E; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Younes, A1
Biamonte, R; Cartenì, G; Colucci, G; Danese, S; de Matteis, A; De Placido, S; Di Maio, M; Di Vagno, G; Febbraro, A; Gasparini, G; Lombardi, AV; Manzione, L; Marinaccio, M; Massidda, B; Nardi, M; Perrone, F; Pignata, S; Pisano, C; Scambia, G; Valerio, MR1
Bian, JS; Chan, E; Chan, SY; Duan, W; Ho, PC; Huang, M; Li, Q; Ng, KY; Nie, YQ; Tan, TM; Tian, Q; Wei, H; Yang, HY; Yu, Q; Zhang, J; Zhou, SF; Zhu, YZ1
Dimitroulis, J; Dimou, E; Karaindros, D; Katis, C; Stathopoulos, GP; Stathopoulos, J; Tsavdaridis, D1
Barbieri, M; Bojke, L; Griffin, S; Main, C; Mather, L; Norman, G; Palmer, S; Riemsma, R; Stark, D1
Bădulescu, A; Bădulescu, F; Popescu, CF; Schenker, M; Stoica, Z1
Bernath, AM; Carroll, TJ; Foster, N; Hillman, S; Jett, JR; Lair, BS; Mailliard, JA; Molina, JR; Nikcevich, D; Tazelaar, HD1
Campos, S; Duska, LR; Falke, R; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV; Smith, LM1
McGuire, WP1
Blohmer, JU; Bourgeois, H; Costa, S; du Bois, A; Geay, JF; Hardy-Bessard, AC; Jackisch, C; Kimmig, R; Kuhn, W; Lortholary, A; Lück, HJ; Meden, H; Meier, W; Möbus, V; Nitz, U; Olbricht, S; Pfisterer, J; Pujade-Lauraine, E; Quaas, J; Reuss, A; Richter, B; Schröder, W; Stähle, A; Wagner, U; Weber, B1
Fangusaro, J; Finlay, J; Rook, J; Rosser, T1
Chatelut, E; Henningsson, A; Karlsson, MO; Kloft, C; Wallin, J1
Collado, MV; García Villanueva, A; Pérez de Oteyza, J; Rojo, R; Ruiz-Tovar, J1
Grønlund, B1
Aravantinos, G; Christodoulou, Ch; Malamos, NA; Rigatos, S; Skarlos, D; Stathopoulos, GP; Stathopoulos, J1
Canales Ugarte, S; Cassinello Espinosa, J1
Bot, BM; Garces, YI; Jett, JR; Kozelsky, TF; Mandrekar, SJ; Martens, JM; Moore, DF; Okuno, SH; Schild, SE; Soori, GS; Wender, DB1
Armstrong, DK; Bookman, MA; Bristow, RE; McGuire, W; Schilder, JM1
Dakhil, S; Dy, GK; Geoffroy, FJ; Jett, JR; Krewer, KD; Krook, J; Kugler, J; Kutteh, L; Mailliard, J; Maurer, M; Rowland, K; Tazelaar, H; Wender, D1
Atkins, JN; Bearden, JD; Crowley, JJ; Dakhil, SR; Dunphy, FR; Gandara, DR; Giguere, JK; Hesketh, PJ; Kelly, K; McCoy, J; Weiss, GR1
Corrado, G; Samaritani, R; Sbiroli, C; Vizza, E1
Camara, O; Fedders, M; Hartmann, M; Kath, R; Oelschläger, H; Schneider, A1
Bogart, JA; Green, MR; Hodgson, LD; Miller, AA; Radford, JE; Rocha Lima, CM; Vokes, EE; Wang, XF1
Baker, SD; Chatelut, E; Mathijssen, RH; Rowinsky, EK; Sparreboom, A; Verweij, J; Wolff, AC1
Lehoczky, O; Pulay, T1
Cui, BX; Jiang, J; Kong, BH; Meng, LH; Su, SL; Wang, B; Wang, LJ; Yang, XS; Zhang, YZ1
Bachvarov, D; Bachvarova, M; L'Espérance, S; Mes-Masson, AM; Tetu, B1
Chen, XY; Lihua, P; Wu, TX1
Eisenkop, SM; McAlpine, JN; Spirtos, NM1
Aravantinos, G; Bafaloukos, D; Bamias, A; Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Papadimitriou, CA; Pectasides, D1
Kamposioras, K; Papaxoinis, G; Pectasides, D; Pectasides, E1
Castleberry, R; Kletzel, M; Kretschmar, C; London, WB; Marcus, R; Murray, K; Zage, PE; Zhang, Y1
Friedrichs, N; Gorschlüter, M; Gressner, O; Mey, U; Popp, H; Sauerbruch, T; Schmidt-Wolf, IG; Strehl, J1
Enomoto, T; Hayashi, K; Iizuka, M; Kuranami, M; Nakakuma, T; Sengoku, N; Watanabe, M; Yoshimura, N1
Hoskins, PJ1
Accario-Winslow, C; Alberts, DS; Argenta, PA; Bookman, MA; Brady, MF; Burger, RA; Colombo, N; De Geest, K; Fowler, JM; Friedlander, M; Harper, PG; McGuire, WP; Mutch, DG; Roth, LM; Swart, AM; Trimble, EL1
Apte, S; Boren, T; Chan, G; Chen, DT; Dressman, H; Hakam, A; Kamath, SG; Lancaster, JM; Wenham, R; Xiong, Y1
Idris, T; Lang, U; Petru, E; Winter, R1
du Bois, A; Gropp, M; Kimmig, R; Kuhn, W; Lück, HJ; Meier, W; Olbricht, S; Pfisterer, J; Reuss, A; Richter, B1
Ji, W; Lü, JM; Ou, GF; Ren, H; Wang, LH; Wang, XZ; Yin, WB; Zhou, ZM1
Friberg, LE; Hansson, EK; Karlsson, MO; Lindman, H; Sandström, M; Wallin, JE1
Benda, J; Boardman, CH; Cella, D; Cohn, DE; McMeekin, DS; Monk, BJ; Ramondetta, LM; Sill, MW1
Bloss, JD; Long, HJ; Monk, BJ; Moore, DH; Omura, GA; Tian, C1
García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L1
Monk, BJ; Tewari, KS1
Aimone, PD; Bolis, G; Danese, S; Lo Russo, D; Mangili, G; Raspagliesi, F; Scambia, G; Scarfone, G; Scollo, P; Villa, A1
Brigulová, K; Cervinka, M; Sedláková, I; Tošner, J1
Benda, J; Boardman, CH; Cella, D; Cohn, D; Huang, HQ; McMeekin, DS; Monk, BJ; Ramondetta, L; Wenzel, L1
Brotto, L; Casado, A; Cervantes, A; Chen, D; D'Hondt, V; Eisenhauer, EA; Elit, L; Germa, JR; Ghatage, P; Grimshaw, R; Hoskins, P; Katsaros, D; Mendiola, C; Ojeda, B; Oza, A; Poveda, A; Provencher, D; Roy, M; Stuart, G; Sugimoto, A; Tu, D; Vergote, I; Zola, P1
Azrak, RG; Rempinski, DR; Rustum, YM; Saifo, MS1
Athanasopoulos, A; Daladimos, T; Karabelis, A; Kosmas, C; Mylonakis, N; Theotikos, E; Tsakonas, G1
Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D1
Amin, MS; Eisenhauer, EA; Hoskins, PJ; Islam, S; O'Brien, AM; Pelletier, LB; Squire, JA; Tu, D; Weberpals, JI1
Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A1
Ambrosone, CB; Bookman, M; Darcy, KM; Deloia, JA; Gallion, H; Krivak, TC; Tian, C1
Alexandre, J; Dauba, J; Durando, X; Gladieff, L; Largillier, R; Lortholary, A; Paraiso, D; Pujade-Lauraine, E; Slama, B; Weber, B1
Adams, S; Alagkiozidis, I; Benencia, F; Carpenito, C; Coukos, G; Facciabene, A; Jonak, Z; June, CH; Powell, DJ; Tsiatas, M1
Cetina, L; Coronel, J; Dueñas-Gonzalez, A1
Ambrosone, CB; Armstrong, DK; Bookman, MA; Darcy, KM; Davis, W; DeLoia, JA; Gallion, H; Krivak, TC; Moysich, K; Tian, C; Zhao, H1
Dorigo, O; Eng, C; Fekete, M; Santiskulvong, C1
Jia, L; Kong, B; Li, D; Xu, Y; Zhang, H; Zhou, XC1
Bian, ML; Higuma, C; Isaka, K; Ito, H; Liang, J; Nishi, H; Sasaki, T1
Arcand, SL; Caceres, KY; Cyr, L; de Ladurantaye, M; Delvoye, N; Létourneau, IJ; Mes-Masson, AM; Meunier, L; Portelance, L; Provencher, DM; Quinn, MC; Shen, Z; Tonin, PN; Wang, LL1
Spigel, DR1
Lin, B; Shao, L; Song, Z; Zhang, Y1
Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G1
Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; McCann, GA; O'Malley, DM; Richardson, DL; Salani, R; Smith, B1
Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP1
Gulbake, A; Hurkat, P; Jain, A; Jain, SK; Kashaw, S; Shilpi, S1
Castiglioni, V; Cesca, M; Decio, A; Giavazzi, R; Rovida, A; Scanziani, E; Scarlato, V1
Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M1
Huang, H; Landrum, LM; Leitao, MM; Long, HJ; Michael, HE; Monk, BJ; Oaknin, A; Penson, RT; Ramondetta, LM; Reid, TJ; Sill, MW; Tewari, KS1
Bamias, A; Bollag, D; Follana, P; Hilpert, F; Kristensen, G; Mirza, MR; Oaknin, A; Pereira, D; Poveda, A; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Sorio, R; Vergote, I; Weber, B; Wimberger, P; Witteveen, P1
Arranz, JA; de Gregorio, N; Freudensprung, U; Friedlander, M; Hales, G; Hilpert, F; Joly, F; King, MT; Lee, CK; Mirza, MR; Pujade-Lauraine, E; Sneller, V; Sorio, R; Stockler, MR; Wenzel, L1
Hamasaki, T; Hisamatsu, T; Kawano, M; Kimura, T; Kishimoto, T; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, K; Takahashi, R; Takahashi, T1
Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q1
Eskander, RN; Tewari, KS1
Morikawa, A; Nagata, C; Okamoto, A; Saito, M; Suzuki, J; Suzuki, K; Takahashi, K; Takakura, S; Tanabe, H; Yanaihara, N1
Dang, NH; Fanale, M; Fayad, L; Feng, L; Fowler, N; Hagemeister, FB; Loyer, E; McLaughlin, P; Nastoupil, L; Oki, Y; Pro, B; Rodriguez, MA; Romaguera, J; Samaniego, F; Westin, JR; Younes, A1
Barnett, JC; Havrilesky, LJ; Leath, CA; Phippen, NT1
Barton, S; Edwards, SJ; Thurgar, E; Trevor, N1
Huang, HQ; Landrum, LM; Leitao, MM; Long, HJ; Method, M; Michael, H; Monk, BJ; Oaknin, A; Penson, RT; Ramondetta, LM; Reid, TJ; Stockman, S; Tewari, KS; Wenzel, LB1
Krill, LS; Tewari, KS1
Matsumoto, K; Onda, T; Yaegashi, N1
Arya, N; Katti, DS1
Jain, A; Jain, SK1
Bamias, A; Hilpert, F; Mitchell, L; Poveda, AM; Pujade-Lauraine, E; Reuss, A; Savarese, A; Scotto, N; Selle, F; Vergote, I; Witteveen, P1
Brotto, L; Brundage, M; Casado, HA; Cervantes, A; Eisenhauer, E; Hoskins, P; Poveda, A; Tu, D; Vergote, I1
Januchowski, R; Nowicki, M; Wojtowicz, K; Zabel, M1
Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB1
Holman, LL; Ren, Y; Westin, SN1
Fujimoto, D; Ito, J; Katakami, N; Kato, R; Kogo, M; Nagata, K; Nakagawa, A; Otoshi, T; Otsuka, K; Sato, Y; Shimizu, R; Teraoka, S; Tomii, K1
Armaiz-Pena, GN; Coleman, RL; Dalton, HJ; Davis, AN; Hansen, JM; Langley, RR; Lin, YG; Merritt, WM; Nick, AM; Pradeep, S; Previs, RA; Sood, AK1
Brown, J; Landrum, LM; Leitao, MM; Long, HJ; Michael, HE; Monk, BJ; Moore, DH; Penson, RT; Poveda, A; Reid, TJ; Sill, MW; Tewari, KS1
Chekerov, R; Ismaeel, F; Richter, R; Roots, I; Sehouli, J; Siepmann, T; Woopen, H1
du Bois, A; Grabowski, JP; Harter, P; Heitz, F; Heitz, J; Kristensen, G; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Traut, A1
Anttila, M; Breda, E; Hanker, LC; Husain, A; Ojeda, B; Pujade-Lauraine, E; Vuylsteke, P; Wang, Y1
Bastiere-Truchot, L; Berton-Rigaud, D; Colombo, N; Del Campo, JM; du Bois, A; Gadducci, A; García, Y; González-Martín, A; Kiermaier, A; Kurzeder, C; Mahner, S; Marmé, F; Martin, N; Ortega, E; Ottevanger, P; Pautier, P; Rau, J; Selle, F1
Belau, AK; Bover-Barcelo, I; Canzler, U; Chekerov, R; Gonzalez-Martin, A; Hanker, LC; Harter, P; Hilpert, F; Keil, E; Klare, P; Kurzeder, C; Mahner, S; Meier, W; Petru, E; Reinthaller, A; Richter, R; Sehouli, J; Wimberger, P; Woopen, H; Zeimet, A1
Brown, J; Burzawa, JK; Byers, LA; Coleman, RL; Frumovitz, M; Munsell, MF; Ramalingam, P1
Coeffic, D; García, Y; Gebski, V; Gibbs, E; González-Martín, A; Hilpert, F; Huizing, M; Kaern, J; Kristensen, G; Lee, CK; Levaché, CB; Lück, HJ; Pujade-Lauraine, E; Roemer-Becuwe, C; Sorio, R; Witteveen, P; Zagouri, F1
Guerra, I; McCormack, M; Munk, VC; Nogueira-Rodrigues, A; Rosen, VM; Sasse, A; Shang, A1
Bonnetain, F; de la Motte Rouge, T; Kalbacher, E; Lesoin, A; Pautier, P1
Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U1
Choi, YS; Jo, DY; Kim, JM; Ko, YB; Lee, HJ; Ryu, H; Song, IC; Yun, HJ1
Bloomfield, A; Dircksen, C; Dorton, R; Kleindl, P; Leamon, CP; Nelson, M; Reddy, JA; Santhapuram, H; Vetzel, M; Vlahov, IR1
Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T1
Andrzejewska, M; Brązert, J; Januchowski, R; Kędzia, W; Klejewski, A; Nowicki, M; Rusek, D; Sobkowski, M; Sterzyńska, K; Świerczewska, M; Wojtowicz, K1
Choi, MC; Jeong, DH; Kang, S; Kim, JW; Kim, KH; Kim, TH; Kim, YB; Kim, YM; Lee, IH; Lee, JW; Lee, JY; Lee, KB; Lee, YJ; Park, JY; Park, SY; Pujade-Lauraine, E1
Nazha, B; Owonikoko, TK1
Andrzejewska, M; Brązert, J; Brązert, M; Januchowski, R; Kaźmierczak, D; Klejewski, A; Nowacka, M; Nowicki, M; Rusek, D; Sterzyńska, K; Świerczewska, M; Wojtowicz, K1
Kim, JC; Kim, JH; Kim, YM; Yoon, YS1
Castellano, G; Torrens, F1
Dhagat, S; Eswari, JS; Yadav, M1
du Bois, A; Harter, P; Hedderich, J; Heilmann, T; Hempel, AM; Hilpert, F; Pfisterer, J; Pujade-Lauraine, E; Saß, S1
Burger, RA; Fruehauf, JP; Kim, JH; Parmakhtiar, B1
Ahmad, M; Akhlaq, M; Danish, Z; Saeed, H; Saleem, Z; Sattar, S1
Asher, R; Friedlander, M; Gebski, V; Gonzalez-Martin, A; Hardy-Bessard, AC; Hilpert, F; Kaminsky, MC; Kurzeder, C; Largillier, R; Lee, CK; Lesoin, A; Lortholary, A; Poveda, A; Pujade-Lauraine, E1
Bastière-Truchot, L; Berger, R; Berton-Rigaud, D; Cardona, A; Colombo, N; du Bois, A; González Martin, A; Greimel, E; Grischke, EM; Hilpert, F; Kroep, JR; Kurzeder, C; Lorusso, D; Lück, HJ; Martinez-Garcia, J; Mirza, MR; Ottevanger, P; Pardo, B; Rau, J; Redondo, A; Selle, F; Vergote, I1
Alvarez Secord, A; Armstrong, DK; Azab, M; Banerjee, S; Basu, B; Birrer, MJ; Blagden, SP; Braly, P; Fleming, GF; Ghamande, S; Hall, GD; Hao, Y; Hirte, HW; Jueliger, S; Keer, H; Kristeleit, R; Markham, MJ; Matei, D; Matulonis, UA; McGuire, WP; Naim, S; Nemunaitis, J; Nephew, KP; Oganesian, A; Oza, AM; Provencher, DM; Roman, LD; Schwartz, B1
Chase, D; Gil, K; Guntupalli, SR; Huang, HQ; Huh, WK; Landrum, LM; Leitao, M; Monk, BJ; Oaknin, A; Penson, RT; Pulaski, HL; Ramondetta, LM; Richardson, D; Robison, K; Salani, R; Sill, MW; Tewari, KS; Wenzel, LB1
Cramer-van der Welle, CM; Groen, HJM; Schramel, FMNH; van de Garde, EMW; van Leeuwen, AS1
Aghajanian, C; Banerjee, S; Berger, R; Boyd, AP; Christy-Bittel, J; Churruca, C; Cibula, D; Clamp, A; Coleman, RL; Colombo, N; Del Campo, JM; Drill, E; Grisham, RN; Hilpert, F; Kalbacher, E; Kristensen, G; Marth, C; Mirza, MR; Monk, BJ; Moore, KN; O'Malley, DM; Oehler, MK; Oza, AM; Pignata, S; Ray-Coquard, I; Romero, I; Sehouli, J; Vergote, I; Vuylsteke, P; Westermann, A1
Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS1
Gu, X; Liu, X; Xu, M; Zeng, T; Zhang, W; Zhang, X; Zhao, F1
Choi, CH; Joung, JG; Kim, BG; Kim, HS; Kim, JW; Kim, S; Lee, JB; Lee, JY; Park, E1
Gabbay, RS; Rubinstein, A1
Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S1
Bhosale, P; Chisholm, GB; Flores-Legarreta, A; Frumovitz, M; Gonzales, NR; Hillman, RT; Jhingran, A; Ramalingam, P; Salvo, G1

Reviews

61 review(s) available for topotecan and paclitaxel

ArticleYear
Membrane transporters in drug development.
    Nature reviews. Drug discovery, 2010, Volume: 9, Issue:3

    Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs

2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery.
    Journal of natural products, 2018, 03-23, Volume: 81, Issue:3

    Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Taxoids

2018
New cytotoxic drugs in clinical development.
    Nouvelle revue francaise d'hematologie, 1991, Volume: 33, Issue:6

    Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids; Topotecan

1991
Novel chemotherapeutic agents in clinical development.
    Current opinion in oncology, 1991, Volume: 3, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Mitomycin; Mitomycins; Paclitaxel; Pyrazoles; Quinazolines; Thiophenes; Topotecan

1991
New natural products in cancer chemotherapy.
    Journal of clinical pharmacology, 1990, Volume: 30, Issue:9

    Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Drugs, Investigational; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Irinotecan; Melanoma; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Topotecan

1990
New drugs for treating small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 1995, Volume: 12 Suppl 3

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan

1995
New chemotherapeutic agents in non-small-cell lung cancer.
    Seminars in oncology, 1993, Volume: 20, Issue:2

    Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; Humans; Interferons; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine

1993
New chemotherapeutic agents for non-small cell lung cancer.
    Chest, 1995, Volume: 107, Issue:6 Suppl

    Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quinoxalines; Sulfanilamides; Taxoids; Topotecan; Vinblastine; Vinorelbine

1995
New directions for chemotherapy in non-small-cell lung cancer.
    Chest, 1993, Volume: 103, Issue:4 Suppl

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine

1993
Promising new therapies in the treatment of advanced ovarian cancer.
    Cancer, 1995, Nov-15, Volume: 76, Issue:10 Suppl

    Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topotecan

1995
New anticancer agents in clinical development.
    Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:11

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; DNA Topoisomerases, Type I; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Paclitaxel; Prodrugs; Taxoids; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan

1995
Promising new agents in oncologic treatment.
    Current opinion in oncology, 1996, Volume: 8, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Mice; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan

1996
Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Remission Induction; Safety; Survival Rate; Topoisomerase I Inhibitors; Topotecan

1997
New options for the treatment of advanced ovarian cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Remission Induction; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome

1997
Future directions in the chemotherapy of ovarian cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15

    Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine

1997
[Lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:13

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine

1997
[Promising new drugs for gynecological cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:13

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Irinotecan; Organoplatinum Compounds; Paclitaxel; Taxoids; Topotecan

1997
["State-of-the-art" chemotherapy for small-cell lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine

1997
Topotecan in combination chemotherapy.
    Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 20

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Paclitaxel; Suramin; Topoisomerase I Inhibitors; Topotecan

1997
New agents in the treatment of small cell lung cancer.
    Chest, 1998, Volume: 113, Issue:1 Suppl

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Menogaril; Paclitaxel; Taxoids; Teniposide; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine

1998
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Topotecan; Vinblastine; Vinorelbine

1998
New agents in the management of advanced non-small cell lung cancer.
    Seminars in oncology, 1998, Volume: 25, Issue:4 Suppl 9

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine

1998
The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies.
    Cancer treatment reviews, 1998, Volume: 24, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Paclitaxel; Topoisomerase I Inhibitors; Topotecan

1998
Chemotherapy in head and neck cancer. Overview of newer agents.
    Hematology/oncology clinics of North America, 1999, Volume: 13, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Organoplatinum Compounds; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids; Topotecan; Vinblastine; Vinorelbine

1999
The role of radiation, with or without chemotherapy, in the management of NSCLC.
    Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:10 Suppl 5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Topotecan; Vinblastine; Vinorelbine

1999
The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphoma.
    Seminars in hematology, 1999, Volume: 36, Issue:4 Suppl 8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Humans; Lymphoma, Non-Hodgkin; Paclitaxel; Salvage Therapy; Topoisomerase I Inhibitors; Topotecan

1999
[Pharmacokinetic monitoring].
    Bulletin du cancer, 2000, Volume: 87, Issue:1

    Topics: Antineoplastic Agents; Body Mass Index; Camptothecin; Colorectal Neoplasms; Drug Interactions; Drug Monitoring; Etoposide; Fluorouracil; Humans; Irinotecan; Liver; Paclitaxel; Topotecan

2000
New chemotherapy agents for small cell lung cancer.
    Chest, 2000, Volume: 117, Issue:4 Suppl 1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Topotecan; Vinblastine; Vinorelbine

2000
Extensive small-cell lung cancer: a treatment overview.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:7 Suppl 5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine

2000
Treatment of extensive stage small cell lung cancer.
    Cancer treatment and research, 2001, Volume: 105

    Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Genes, Dominant; Growth Substances; Humans; Irinotecan; Lung Neoplasms; Metalloendopeptidases; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasm Staging; Oncogenes; Paclitaxel; Palliative Care; Protease Inhibitors; Randomized Controlled Trials as Topic; Salvage Therapy; Signal Transduction; Taxoids; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine

2001
Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience.
    Seminars in oncology, 2001, Volume: 28, Issue:2 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Topotecan

2001
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2001, Volume: 11 Suppl 1

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; DNA Adducts; Female; Gemcitabine; Humans; Immunologic Factors; Liposomes; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topoisomerase I Inhibitors; Topotecan

2001
Treatment of advanced ovarian cancer.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37 Suppl 9

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Liposomes; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Topotecan

2001
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2001, Volume: 34 Suppl 4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine

2001
The role of gemcitabine-based doublets in the management of ovarian carcinoma.
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine

2002
Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan

2002
[Developed new agents for lung cancer].
    Nihon Geka Gakkai zasshi, 2002, Volume: 103, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine

2002
Epithelial ovarian cancer.
    Current treatment options in oncology, 2002, Volume: 3, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine

2002
[Nogitecan hydrochloride].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 5

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Topotecan

2002
Update on the role of topotecan in the treatment of recurrent ovarian cancer.
    The oncologist, 2002, Volume: 7 Suppl 5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Rate; Topotecan

2002
[Gemicitabine in the treatment of epithelial ovarian cancer].
    Bulletin du cancer, 2002, Volume: 89 Spec No

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Multicenter Studies as Topic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prodrugs; Remission Induction; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine

2002
Current therapies in ovarian cancer.
    Cancer investigation, 2003, Volume: 21, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; Drug Approval; Female; Forecasting; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Multicenter Studies as Topic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Topotecan; Treatment Outcome; United States; United States Food and Drug Administration

2003
The role of topotecan in the treatment of advanced cervical cancer.
    Gynecologic oncology, 2003, Volume: 90, Issue:3 Pt 2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Drug Synergism; Etoposide; Female; Humans; Paclitaxel; Topotecan; Uterine Cervical Neoplasms

2003
Workshop: options for therapy in ovarian cancer.
    Gynecologic oncology, 2003, Volume: 90, Issue:3 Pt 2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan

2003
Recurrent ovarian cancer: how important is it to treat to disease progression?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22

    Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan

2004
Ovarian cancer: review of the National Institute for Clinical Excellence (NICE) guidance recommendations.
    Cancer investigation, 2004, Volume: 22, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Female; Guidelines as Topic; Humans; Liposomes; Ovarian Neoplasms; Paclitaxel; Topotecan

2004
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2006, Volume: 10, Issue:9

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cost-Benefit Analysis; Doxorubicin; Female; Humans; Liposomes; Ovarian Neoplasms; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan

2006
Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
    Danish medical bulletin, 2006, Volume: 53, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Denmark; Diagnostic Imaging; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Outcome

2006
Topotecan for ovarian cancer.
    The Cochrane database of systematic reviews, 2008, 04-16, Issue:2

    Topics: Antineoplastic Agents; Doxorubicin; Female; Humans; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Topotecan

2008
Chemotherapy for recurrent cervical cancer.
    Cancer treatment reviews, 2008, Volume: 34, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms

2008
Double high-dose chemotherapy and stem cell transplantation in adult Wilms' tumor.
    Future oncology (London, England), 2010, Volume: 6, Issue:11

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cyclophosphamide; Etoposide; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Melphalan; Paclitaxel; Radiography; Salvage Therapy; Topotecan; Transplantation, Autologous; Wilms Tumor; Young Adult

2010
Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer.
    Expert opinion on drug metabolism & toxicology, 2011, Volume: 7, Issue:12

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine

2011
First-line chemotherapy in epithelial ovarian cancer.
    Clinical obstetrics and gynecology, 2012, Volume: 55, Issue:1

    Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A

2012
Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials.
    Journal of chemotherapy (Florence, Italy), 2012, Volume: 24, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Topotecan

2012
Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer.
    Current opinion in obstetrics & gynecology, 2014, Volume: 26, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mass Screening; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Topotecan; Uterine Cervical Neoplasms

2014
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2015, Volume: 19, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Gemcitabine; Health Care Costs; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tetrahydroisoquinolines; Topotecan; Trabectedin; Treatment Outcome; United Kingdom

2015
Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms

2015
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids

2015
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
    Gynecologic oncology, 2016, Volume: 140, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polypharmacy; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Withholding Treatment; Young Adult

2016
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms

2017

Trials

97 trial(s) available for topotecan and paclitaxel

ArticleYear
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Thrombocytopenia; Topotecan; United States

1995
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan

1996
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Sepsis; Topotecan

1996
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Vomiting

1997
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Topotecan

1997
Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Gynecologic oncology, 1997, Volume: 66, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Analysis; Topotecan; Treatment Outcome

1997
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Regression Analysis; Topotecan; Treatment Outcome

1998
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome

1998
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan

1999
Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer.
    Cancer, 1999, Mar-01, Volume: 85, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Recombinant Proteins; Thrombocytopenia; Topotecan; Treatment Outcome

1999
Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients.
    Anti-cancer drugs, 1999, Volume: 10, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platelet Count; Prospective Studies; Thrombocytopenia; Topotecan

1999
Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Topotecan; Treatment Outcome

1999
Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study.
    Journal of surgical oncology, 1999, Volume: 72, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Salvage Therapy; Topotecan

1999
The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?
    European journal of gynaecological oncology, 2000, Volume: 21, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan

2000
A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Gynecologic oncology, 2000, Volume: 78, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Lactones; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan

2000
Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Sep-15, Volume: 18, Issue:18

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Middle Aged; Neoplasms; Paclitaxel; Platelet Count; Recombinant Proteins; Taxoids; Topotecan

2000
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
    Gynecologic oncology, 2000, Volume: 79, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan

2000
Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-15, Volume: 18, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epithelium; Feasibility Studies; Female; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Survival Rate; Topotecan; Vomiting

2000
Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel.
    Gynecologic oncology, 2001, Volume: 80, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm, Residual; Paclitaxel; Topotecan

2001
Phase I study of docetaxel and topotecan in patients with solid tumors.
    Cancer chemotherapy and pharmacology, 2000, Volume: 46, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Topotecan

2000
Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
    Oncology, 2001, Volume: 60, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recurrence; Topotecan; Treatment Outcome

2001
Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Feb-15, Volume: 19, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Stomatitis; Topotecan

2001
Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-01, Volume: 19, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cross-Over Studies; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Europe; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Survival Rate; Topotecan; United States

2001
Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
    Gynecologic oncology, 2001, Volume: 81, Issue:2

    Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan

2001
Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer.
    Gynecologic oncology, 2001, Volume: 81, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Topotecan

2001
A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study.
    British journal of cancer, 2001, May-04, Volume: 84, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Topotecan

2001
Phase I dose escalation study of topotecan combined with alternating schedules of paclitaxel and carboplatin in advanced solid tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Topotecan; Treatment Outcome

2001
Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutrophils; Paclitaxel; Topotecan; Treatment Outcome

2001
A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors.
    Cancer, 2001, Sep-01, Volume: 92, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Statistics, Nonparametric; Survival Rate; Topotecan

2001
Feasibility of oral topotecan plus intravenous paclitaxel in advanced non-small-cell lung cancer.
    Oncology, 2001, Volume: 61 Suppl 1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Topotecan; Treatment Outcome

2001
Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
    Gynecologic oncology, 2002, Volume: 85, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Topotecan

2002
Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Cancer, 2002, May-01, Volume: 94, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Topotecan; Treatment Outcome

2002
A phase I study of weekly topotecan and Paclitaxel in previously treated epithelial ovarian carcinoma patients.
    Gynecologic oncology, 2002, Volume: 87, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Dose-Response Relationship, Drug; Drug Administration Schedule; Epithelial Cells; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan

2002
Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer.
    The oncologist, 2003, Volume: 8, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Topotecan; Treatment Outcome

2003
Phase I trial of carboplatin and paclitaxel with escalating doses of oral topotecan in patients with solid tumors.
    American journal of clinical oncology, 2003, Volume: 26, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Topotecan

2003
[Own experiences in salvage chemotherapy of ovarian cancer--a preliminary report].
    Ginekologia polska, 2002, Volume: 73, Issue:11

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Time Factors; Topotecan; Treatment Outcome

2002
Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Cancer, 2003, May-15, Volume: 97, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Illinois; Indiana; Iowa; Lung Neoplasms; Male; Middle Aged; Minnesota; Nebraska; Neoplasm Staging; North Dakota; Paclitaxel; South Dakota; Survival Analysis; Topotecan; Treatment Outcome

2003
A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan

2003
Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5.
    Gynecologic oncology, 2003, Volume: 90, Issue:2 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Liposomes; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Topotecan

2003
Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Topotecan

2003
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Disease Progression; Drug Administration Schedule; Female; Humans; Incidence; Infusions, Intravenous; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Sensitivity and Specificity; Survival Analysis; Topotecan

2004
Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?
    British journal of cancer, 2004, Jan-26, Volume: 90, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carcinoma; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Reference Values; Topotecan; Treatment Outcome; World Health Organization

2004
Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Topotecan

2004
Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.
    Gynecologic oncology, 2004, Volume: 92, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms

2004
A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer.
    British journal of cancer, 2004, Feb-23, Volume: 90, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Analysis; Topotecan; Treatment Outcome

2004
Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
    Onkologie, 2004, Volume: 27, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure

2004
Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study.
    Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan

2004
70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.
    International journal of radiation oncology, biology, physics, 2004, Jun-01, Volume: 59, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Remission Induction; Small Cell Lung Carcinoma; Survival Analysis; Topotecan

2004
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-01, Volume: 22, Issue:13

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome

2004
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
    Gynecologic oncology, 2004, Volume: 94, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan

2004
Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Oct-15, Volume: 22, Issue:20

    Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infant; Male; Neuroblastoma; Paclitaxel; Survival Rate; Topotecan

2004
A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
    Journal of neuro-oncology, 2005, Volume: 71, Issue:3

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Filgrastim; Glioblastoma; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Recombinant Proteins; Thrombocytopenia; Topotecan; Treatment Outcome

2005
A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Outcome

2005
Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study.
    Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Humans; Male; Middle Aged; Paclitaxel; Topotecan

2006
Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
    The oncologist, 2005, Volume: 10, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Paclitaxel; Topotecan

2005
Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Injections, Subcutaneous; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutrophils; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Recurrence; Topotecan; Treatment Outcome

2006
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.
    BMC cancer, 2006, Jan-07, Volume: 6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Severity of Illness Index; Time Factors; Topotecan

2006
Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Topotecan

2006
Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
    American journal of clinical oncology, 2006, Volume: 29, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Topotecan; Treatment Outcome

2006
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
    Gynecologic oncology, 2006, Volume: 103, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan

2006
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Journal of the National Cancer Institute, 2006, Aug-02, Volume: 98, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Female; France; Germany; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Prospective Studies; Quality of Life; Survival Analysis; Topotecan; Treatment Failure

2006
Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Remission Induction; Thrombocytopenia; Topotecan; Treatment Outcome

2007
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
    International journal of radiation oncology, biology, physics, 2007, Mar-15, Volume: 67, Issue:4

    Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality Control; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topotecan

2007
A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2007, Volume: 105, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Topotecan

2007
Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Topotecan

2006
Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Probability; Prognosis; Risk Factors; Survival Analysis; Topotecan

2006
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Severity of Illness Index; Survival Rate; Topotecan; Treatment Outcome

2007
[Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Zhonghua fu chan ke za zhi, 2007, Volume: 42, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Topotecan; Treatment Outcome

2007
Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
    Gynecologic oncology, 2008, Volume: 111, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Topotecan

2008
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-20, Volume: 27, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Topotecan

2009
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekolog
    Gynecologic oncology, 2009, Volume: 114, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Rate; Topotecan

2009
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-01, Volume: 27, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Quality of Life; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine; Young Adult

2009
Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:16

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Outcome; Young Adult

2010
Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2010, Volume: 119, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine

2010
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
    Journal of the National Cancer Institute, 2010, Oct-20, Volume: 102, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Staging; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Failure

2010
Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Topotecan

2012
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2012, Volume: 124, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Polymorphism, Genetic; Topotecan; Young Adult

2012
Improved survival with bevacizumab in advanced cervical cancer.
    The New England journal of medicine, 2014, Feb-20, Volume: 370, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Analysis; Topotecan; Uterine Cervical Neoplasms

2014
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, May-01, Volume: 32, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Topotecan

2014
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, May-01, Volume: 32, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Self Report; Topotecan; Treatment Outcome

2014
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult

2014
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
    British journal of haematology, 2014, Volume: 167, Issue:2

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Male; Middle Aged; Paclitaxel; Recurrence; Rituximab; Salvage Therapy; Survival Analysis; Topotecan; Treatment Outcome; Young Adult

2014
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
    The Lancet. Oncology, 2015, Volume: 16, Issue:3

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Quality of Life; Risk Factors; Surveys and Questionnaires; Time Factors; Topotecan; Treatment Outcome; United States; Uterine Cervical Neoplasms

2015
Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-10, Volume: 33, Issue:32

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Polyethylene Glycols; Prognosis; Risk Factors; Topotecan; Treatment Outcome

2015
Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Image; Carboplatin; Cisplatin; Disease-Free Survival; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Quality of Life; Surveys and Questionnaires; Topotecan

2016
Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Dec-15, Volume: 21, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Humans; Kaplan-Meier Estimate; Neoplasm Staging; Odds Ratio; Paclitaxel; Prognosis; Survival Analysis; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms

2015
Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
    Gynecologic oncology, 2016, Volume: 142, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Topotecan

2016
Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan

2016
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality of Life; Topotecan

2016
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
    Gynecologic oncology, 2017, Volume: 144, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Hypertension; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Selection; Platinum Compounds; Polyethylene Glycols; Topotecan

2017
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Oct-10, Volume: 35, Issue:29

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome

2017
Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 117

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nomograms; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Topotecan

2019
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2019, Volume: 29, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Double-Blind Method; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Progression-Free Survival; Receptor, ErbB-3; RNA, Messenger; Topotecan

2019
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 03-01, Volume: 26, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Safety; Polyethylene Glycols; Survival Rate; Topotecan; Treatment Outcome

2020
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2020, Volume: 30, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Humans; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Quality of Life; Topotecan; Uterine Cervical Neoplasms; Withholding Treatment

2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 11-10, Volume: 38, Issue:32

    Topics: Adult; Aged; Benzimidazoles; Cystadenocarcinoma, Serous; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Protein Kinase Inhibitors; Topotecan; Young Adult

2020
Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial.
    Journal of gynecologic oncology, 2022, Volume: 33, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan

2022

Other Studies

153 other study(ies) available for topotecan and paclitaxel

ArticleYear
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
    Bioorganic & medicinal chemistry letters, 2004, Feb-23, Volume: 14, Issue:4

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Cell Membrane; Drug Resistance, Microbial; Drug Resistance, Multiple; Ligands; Models, Molecular

2004
Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.
    Pharmaceutical research, 2004, Volume: 21, Issue:5

    Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport, Active; Caco-2 Cells; Cell Membrane Permeability; Humans; Intestinal Absorption; Mice; Mice, Knockout; Pharmacokinetics; Spectrometry, Mass, Electrospray Ionization

2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:11

    Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity

2010
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:2

    Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity

2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Design and synthesis of new 7-(N-substituted-methyl)-camptothecin derivatives as potent cytotoxic agents.
    Bioorganic & medicinal chemistry letters, 2014, Aug-15, Volume: 24, Issue:16

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; KB Cells; Molecular Structure; Structure-Activity Relationship

2014
Synthesis and antitumor activity of novel substituted uracil-1'(N)-acetic acid ester derivatives of 20(S)-camptothecins.
    European journal of medicinal chemistry, 2017, Jan-05, Volume: 125

    Topics: Acetates; Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Humans; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Uracil

2017
Synthesis, Biological Evaluation, and Autophagy Mechanism of 12
    ACS medicinal chemistry letters, 2017, Feb-09, Volume: 8, Issue:2

    Topics:

2017
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
    Journal of the National Cancer Institute, 1994, Oct-19, Volume: 86, Issue:20

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Computer Simulation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Antagonism; Drug Synergism; Etoposide; Humans; Paclitaxel; Teratocarcinoma; Topotecan; Tumor Cells, Cultured; Vincristine

1994
[Ovarian cancer. The new chemotherapeutic agents].
    Soins; la revue de reference infirmiere, 1995, Issue:599

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Topotecan

1995
In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
    British journal of cancer, 1997, Volume: 75, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Glutathione; Humans; Lung Neoplasms; Neoplasm Proteins; Paclitaxel; Taxoids; Topotecan; Tumor Cells, Cultured

1997
Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan.
    British journal of cancer, 1997, Volume: 75, Issue:8

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Survival; DNA, Neoplasm; Female; Humans; Hydrogen-Ion Concentration; Mammary Neoplasms, Experimental; Mice; Mitoxantrone; Paclitaxel; Topotecan; Tumor Cells, Cultured; Urinary Bladder Neoplasms

1997
Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy.
    International journal of oncology, 1998, Volume: 12, Issue:3

    Topics: Adenoviridae; Antineoplastic Agents; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p16; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G1 Phase; Glioma; Humans; Paclitaxel; Recombinant Proteins; Time Factors; Topotecan; Transfection

1998
Back to the future: multiagent chemotherapy in ovarian cancer revisited.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Female; Humans; Laparotomy; Ovarian Neoplasms; Paclitaxel; Topotecan

1999
Topotecan: new preparation. No proven benefit.
    Prescrire international, 1998, Volume: 7, Issue:34

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Female; France; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Outcome

1998
Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin.
    Molecular pharmacology, 1999, Volume: 56, Issue:2

    Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; DNA Repair; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Paclitaxel; Topotecan; Tumor Cells, Cultured

1999
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
    International journal of oncology, 1999, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured

1999
Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients.
    International journal of oncology, 1999, Volume: 15, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Ovarian Neoplasms; Paclitaxel; Prognosis; Salvage Therapy; Survival Analysis; Survival Rate; Time Factors; Topotecan; Treatment Outcome

1999
Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
    Experimental cell research, 1999, Dec-15, Volume: 253, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carmustine; Cell Death; Cell Division; Cisplatin; Clone Cells; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Gene Expression Regulation, Neoplastic; Genes, Dominant; Glioma; Humans; In Vitro Techniques; Paclitaxel; Point Mutation; Radiotherapy; Teniposide; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vincristine

1999
Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Caspase 8; Caspase 9; Caspases; Cisplatin; Deoxycytidine; Fas Ligand Protein; fas Receptor; Flow Cytometry; Gemcitabine; Genes, p53; Humans; Lung Neoplasms; Membrane Glycoproteins; Paclitaxel; Recombinant Proteins; Signal Transduction; Topotecan; Transfection; Tumor Cells, Cultured

2000
Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Doxorubicin; Ellipticines; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Pleural Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine

2000
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
    International journal of cancer, 2000, Mar-01, Volume: 85, Issue:5

    Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carboplatin; Cell Division; Cell Line; Cell Line, Transformed; Cell Survival; Cisplatin; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Doxorubicin; Epithelial Cells; Etoposide; Female; Genes, erbB-2; Humans; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Receptor, ErbB-2; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured

2000
Adaptation of solid phase extraction to an automated column switching method for online sample cleanup as the basis of a facile and sensitive high-performance liquid chromatographic assay for paclitaxel in human plasma.
    Journal of pharmaceutical and biomedical analysis, 1999, Volume: 21, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Doxorubicin; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Paclitaxel; Reproducibility of Results; Topotecan

1999
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Survival Rate; Taxoids; Thiophenes; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured

2000
Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.
    Investigational new drugs, 2000, Volume: 18, Issue:2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Cell Cycle; Cell Survival; Docetaxel; Drug Interactions; Enzyme Inhibitors; Humans; Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured

2000
Modern treatment of ovarian cancer.
    Scottish medical journal, 2000, Volume: 45, Issue:2

    Topics: Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan

2000
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:18

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Sesquiterpenes; Topotecan; Transplantation, Heterologous

2000
Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay.
    Anti-cancer drugs, 2000, Volume: 11, Issue:10

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Female; Humans; Luminescent Measurements; Paclitaxel; Topotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Vulvar Neoplasms

2000
Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer.
    Japanese journal of clinical oncology, 2001, Volume: 31, Issue:2

    Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prospective Studies; Topotecan

2001
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2001, Volume: 32, Issue:2

    Topics: Amino Acid Substitution; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; DNA Mutational Analysis; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Isoenzymes; Ki-67 Antigen; Life Tables; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Mutation, Missense; Neoplasm Proteins; Paclitaxel; Point Mutation; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Teniposide; Topotecan; Treatment Outcome; Vault Ribonucleoprotein Particles

2001
Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer.
    Cancer research, 2001, May-15, Volume: 61, Issue:10

    Topics: Amino Acid Sequence; Azacitidine; Base Sequence; Chromosome Mapping; Cisplatin; Cloning, Molecular; Decitabine; DNA, Neoplasm; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; In Situ Hybridization, Fluorescence; Loss of Heterozygosity; Molecular Sequence Data; Ovarian Neoplasms; Oximes; Paclitaxel; Piperazines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid; Topotecan; Transfection; Tumor Cells, Cultured

2001
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.
    International journal of cancer, 2001, Jul-15, Volume: 93, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Cell Division; Cisplatin; Doxorubicin; Drug Combinations; ErbB Receptors; Humans; Oligonucleotides, Antisense; Paclitaxel; Topotecan; Tumor Cells, Cultured

2001
Clonal heterogeneity of p53 mutations in ovarian cancer.
    International journal of oncology, 2001, Volume: 19, Issue:2

    Topics: Antineoplastic Agents; bcl-2-Associated X Protein; Cisplatin; Clone Cells; DNA Mutational Analysis; DNA, Neoplasm; Female; Genetic Heterogeneity; Humans; Immunoblotting; Lethal Dose 50; Mutation; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single-Stranded Conformational; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2001
Synergistic interaction between topotecan and microtubule-interfering agents.
    Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; bcl-X Protein; Blotting, Western; Cell Cycle; Colonic Neoplasms; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Enzyme Inhibitors; Formazans; Humans; Microtubules; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tetrazolium Salts; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Vinblastine

2001
S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function.
    The Journal of biological chemistry, 2002, Jan-11, Volume: 277, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line; Checkpoint Kinase 1; DNA Repair; Doxorubicin; Doxycycline; Enzyme Inhibitors; Etoposide; Flow Cytometry; G2 Phase; Humans; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Signal Transduction; Topoisomerase I Inhibitors; Topotecan

2002
Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action.
    The Journal of pharmacology and experimental therapeutics, 2001, Volume: 299, Issue:3

    Topics: Antineoplastic Agents; Cell Division; Cyanides; Etoposide; Guanidines; Humans; Paclitaxel; Time Factors; Topotecan; Tumor Cells, Cultured

2001
Chemotherapy and pregnancy.
    Clinical obstetrics and gynecology, 2002, Volume: 45, Issue:1

    Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cytarabine; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Fetus; Humans; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Topotecan; Trastuzumab; Vinblastine; Vincristine

2002
Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity.
    Cancer research, 2002, Mar-15, Volume: 62, Issue:6

    Topics: Amino Acid Sequence; Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cell Survival; DNA Damage; Humans; Ligases; Mitosis; Molecular Sequence Data; Neoplasm Proteins; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Protein Structure, Tertiary; Stress, Physiological; Topotecan; Tumor Cells, Cultured; Ubiquitin; Ubiquitin-Protein Ligases

2002
Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study.
    Anti-cancer drugs, 2002, Volume: 13, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; DNA Topoisomerases, Type I; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukocytes; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured

2002
Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma.
    Cancer, 2002, Apr-01, Volume: 94, Issue:7

    Topics: Age Factors; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Topotecan

2002
Intraperitoneal adenovirus-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer.
    Cancer gene therapy, 2002, Volume: 9, Issue:5

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Female; Genetic Therapy; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Treatment Outcome; Tumor Cells, Cultured

2002
Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells.
    Cytokine, 2002, Mar-07, Volume: 17, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Northern; Blotting, Western; Caspase 3; Caspases; Cell Division; DNA, Complementary; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Genetic Vectors; Humans; Interleukin-6; Interleukin-8; Mitoxantrone; Osteosarcoma; Paclitaxel; Phenotype; RNA; Tetrazolium Salts; Thiazoles; Time Factors; Topotecan; Transfection; Tumor Cells, Cultured

2002
Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Flow Cytometry; Gemcitabine; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured; Vinblastine; Vinorelbine

2002
Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Cancer, 2002, Oct-15, Volume: 95, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome

2002
VIII International Conference on malignant lymphoma. June 12-15, 2002 Lugano, Switzerland.
    Clinical lymphoma, 2002, Volume: 3, Issue:2

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Lymphoma; Lymphoma, Mantle-Cell; Middle Aged; Paclitaxel; Prednisone; Rituximab; Time Factors; Topotecan; Treatment Outcome; Vincristine

2002
Early detection and successful treatment of drug-induced pneumonitis with corticosteroids.
    Cancer investigation, 2002, Volume: 20, Issue:7-8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Male; Paclitaxel; Pneumonia; Prednisone; Radiography, Thoracic; Tomography, X-Ray Computed; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine

2002
The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours.
    Cancer detection and prevention, 2003, Volume: 27, Issue:1

    Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Endometrial Neoplasms; Female; Fluorouracil; Genital Neoplasms, Female; Humans; Neoplasm Staging; Paclitaxel; Retrospective Studies; Tetrazolium Salts; Topotecan; Toxicity Tests; Treatment Outcome; Uterine Cervical Neoplasms

2003
[Preclinical studies of concomitant chemoradiation].
    Medicina (Kaunas, Lithuania), 2003, Volume: 39, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Child; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Radiation Tolerance; Time Factors; Topotecan; Transplantation, Heterologous

2003
A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.
    The journal of obstetrics and gynaecology research, 2003, Volume: 29, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Rate; Thrombocytopenia; Topotecan; Treatment Failure

2003
Prolonged stabilization of platinum/paclitaxel-refractory ovarian cancer with topotecan: a case report and review of the literature.
    Clinical and experimental obstetrics & gynecology, 2003, Volume: 30, Issue:2-3

    Topics: Adenocarcinoma, Papillary; Agranulocytosis; Drug Resistance, Neoplasm; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Quality of Life; Topotecan

2003
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.
    European journal of pharmacology, 2003, Jul-25, Volume: 473, Issue:2-3

    Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Division; Cell Line; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Drug Screening Assays, Antitumor; Fenretinide; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topotecan

2003
Apoptotic pathways of epothilone BMS 310705.
    Gynecologic oncology, 2003, Volume: 91, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspases; Cytochrome c Group; Drug Resistance, Neoplasm; Enzyme Activation; Epothilones; Female; Humans; Irinotecan; Isoenzymes; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured

2003
Topotecan as first-line therapy for small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Forecasting; Humans; Lung Neoplasms; Paclitaxel; Platinum; Topotecan

2003
Combination chemotherapy with topotecan for non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Vinblastine; Vinorelbine

2003
Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment.
    Gynecologic oncology, 2004, Volume: 92, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Doxorubicin; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Quality of Life; Topotecan

2004
Recurrent ovarian cancer.
    Onkologie, 2004, Volume: 27, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure

2004
Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer.
    Gynecologic oncology, 2004, Volume: 93, Issue:1

    Topics: Adolescent; Adult; Aged; Deoxycytidine; Drug Costs; Drug Resistance, Neoplasm; Female; Gemcitabine; Health Care Costs; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Topotecan

2004
[Structure-activity relationship analysis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Camptothecin; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Imatinib Mesylate; Irinotecan; Macrolides; Oligopeptides; Paclitaxel; Piperazines; Pyrimidines; Quinazolines; Structure-Activity Relationship; Taxoids; Topotecan; Vinblastine

2004
A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
    Cancer, 2004, Jun-15, Volume: 100, Issue:12

    Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type I; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphocytes; Male; Middle Aged; Neoplasms; Paclitaxel; Topotecan

2004
The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Gynecologic oncology, 2004, Volume: 94, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Genes, MDR; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Topotecan

2004
Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
    Gynecologic oncology, 2004, Volume: 94, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carboplatin; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Caspases; Cell Line, Tumor; Chondrocytes; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Endothelium, Vascular; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Osteoprotegerin; Ovarian Neoplasms; Paclitaxel; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Tumor Necrosis Factor-alpha

2004
Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
    Gynecologic oncology, 2004, Volume: 94, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prognosis; Retrospective Studies; Topotecan

2004
Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality-of-life evaluation?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9

    Topics: Antineoplastic Agents; Female; Follow-Up Studies; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Time Factors; Topotecan; Treatment Outcome

2004
In regard to Bogart et al.: 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage non-small-cell lung cancer: Analysis of cancer and leukemia group B study 39808 (Int J Radiat Oncol Biol Phys 2004;59:460-468).
    International journal of radiation oncology, biology, physics, 2004, Dec-01, Volume: 60, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy Dosage; Recurrence; Topotecan

2004
[Status report on the chemotherapy of ovarian cancer at special cancer centers in Hungary (2002-2003)].
    Magyar onkologia, 2004, Volume: 48, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Docetaxel; Doxorubicin; Female; Humans; Hungary; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Retrospective Studies; Taxoids; Topotecan; Treatment Outcome

2004
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.
    Gynecologic oncology, 2005, Volume: 96, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Cell Line, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Topotecan; Xenograft Model Antitumor Assays

2005
CA125 Nadir values as a prognostic factor in epithelial ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-01, Volume: 23, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Prognosis; Topotecan

2005
Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.
    Gynecologic oncology, 2005, Volume: 98, Issue:3

    Topics: Cisplatin; Cyclophosphamide; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Neoplasm Metastasis; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Topotecan

2005
Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.
    Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Deoxycytidine; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Thyroid Neoplasms; Topotecan; Vinblastine; Vinorelbine

2005
Cancer cell adaptation to chemotherapy.
    BMC cancer, 2005, Jul-18, Volume: 5

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin; Cell Line, Tumor; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Neoplasms; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topotecan; Treatment Outcome; Up-Regulation

2005
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
    Cancer research, 2005, Aug-01, Volume: 65, Issue:15

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan

2005
Non-enrolment of ovarian cancer patients in clinical trials: reasons and background.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Patient Participation; Patient Selection; Prospective Studies; Retrospective Studies; Topotecan

2005
Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.
    Gynecologic oncology, 2006, Volume: 100, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Complementary Therapies; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Genistein; Glucuronides; Humans; Isoflavones; Middle Aged; Ovarian Neoplasms; Paclitaxel; Soy Milk; Topotecan

2006
Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease.
    Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chronic Disease; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Secondary Prevention; Topotecan

2005
Topotecan is a substrate for multidrug resistance associated protein 4.
    Current drug metabolism, 2006, Volume: 7, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carrier Proteins; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; DNA, Complementary; Drug Resistance, Neoplasm; Humans; Indicators and Reagents; Multidrug Resistance-Associated Proteins; Paclitaxel; Topotecan; Transfection

2006
The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
    Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2005, Volume: 46, Issue:4

    Topics: CA-125 Antigen; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Topotecan; Treatment Outcome

2005
Is it time for some new approaches for treating advanced ovarian cancer?
    Journal of the National Cancer Institute, 2006, Aug-02, Volume: 98, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Multicenter Studies as Topic; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Failure

2006
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:3

    Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cerebral Ventricle Neoplasms; Combined Modality Therapy; Consciousness Disorders; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Etoposide; Female; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Hypophysectomy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pituitary Neoplasms; Temozolomide; Thiotepa; Topotecan

2008
Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Sep-15, Volume: 12, Issue:18

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Interactions; Etoposide; Female; Humans; Liver; Male; Middle Aged; Models, Theoretical; Neutropenia; Neutrophils; Paclitaxel; Sex Characteristics; Taxoids; Topotecan

2006
Papillary serous carcinoma of peritoneum: presentation of 2 cases.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:10

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Postoperative Care; Radiography, Abdominal; Time Factors; Tomography, X-Ray Computed; Topotecan; Treatment Outcome

2006
Cerebral and parotid metachronous metastases from an ovarian carcinoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:11

    Topics: Adenocarcinoma, Mucinous; Anticonvulsants; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Parotid Neoplasms; Supratentorial Neoplasms; Topotecan

2006
Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
    BMC cancer, 2007, Apr-15, Volume: 7

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Colostomy; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Epoetin Alfa; Erythropoietin; Fatal Outcome; Female; Follow-Up Studies; Hemorrhage; Humans; Intestinal Obstruction; Karnofsky Performance Status; Laparotomy; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Peritoneal Neoplasms; Recombinant Proteins; Salvage Therapy; Topotecan; Urinary Bladder Neoplasms; Vitamins

2007
Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma.
    Journal of cancer research and clinical oncology, 2007, Volume: 133, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Doxorubicin; Female; Humans; Markov Chains; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Topotecan

2007
Developmental chemotherapy and management of recurrent ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10 Suppl

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome

2003
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Body Size; Body Surface Area; Body Weight; Camptothecin; Carboplatin; Cisplatin; Cytosine; Dioxolanes; Docetaxel; Doxorubicin; Humans; Irinotecan; Metabolic Clearance Rate; Obesity; Paclitaxel; Taxoids; Topotecan

2007
[Evaluation of second-line chemotherapies most often used in recurrent epithelial ovarian cancer].
    Orvosi hetilap, 2007, Dec-09, Volume: 148, Issue:49

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan; Treatment Outcome

2007
Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids.
    BMC genomics, 2008, Feb-26, Volume: 9

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Gene Regulatory Networks; Humans; Ovarian Neoplasms; Paclitaxel; Spheroids, Cellular; Topotecan

2008
Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays.
    Gynecologic oncology, 2008, Volume: 110, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Topotecan

2008
Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
    Pediatric blood & cancer, 2008, Volume: 51, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infant; Male; Neuroblastoma; Paclitaxel; Survival Rate; Topotecan; Transplantation Conditioning; Treatment Outcome; Vincristine; Young Adult

2008
Long-term survival of a patient with small cell lung cancer after nine lines of chemotherapy and radiation.
    Onkologie, 2008, Volume: 31, Issue:8-9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome

2008
[A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Combinations; Female; Humans; Mitoxantrone; Neoplasm Staging; Oxonic Acid; Paclitaxel; Tegafur; Time Factors; Tomography, X-Ray Computed; Topotecan

2008
Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-20, Volume: 27, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Failure

2009
MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.
    Gynecologic oncology, 2009, Volume: 113, Issue:2

    Topics: Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Linear Models; MicroRNAs; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Taxoids; Topotecan

2009
Topotecan-induced long-term remission of an advanced endometrial cancer after treatment with cisplatinum, an anthracycline and paclitaxel.
    Anticancer research, 2009, Volume: 29, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Remission Induction; Topotecan

2009
[Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Topotecan

2009
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cell Enlargement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Fluorouracil; Humans; Models, Biological; Myelopoiesis; Neoplasms; Neutrophils; Observation; Paclitaxel; Precision Medicine; Taxoids; Topotecan

2010
Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.
    Gynecologic oncology, 2010, Volume: 116, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Disease-Free Survival; Female; Humans; Ifosfamide; Logistic Models; Middle Aged; Models, Statistical; Multivariate Analysis; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult

2010
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine

2010
The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Synergism; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Salvage Therapy; Topotecan; Uterine Cervical Neoplasms

2010
Chemoresistance testing of human ovarian cancer cells and its in vitro model.
    Toxicology in vitro : an international journal published in association with BIBRA, 2010, Volume: 24, Issue:8

    Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Gemcitabine; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel; Topotecan

2010
Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers.
    Molecular cancer, 2010, Dec-02, Volume: 9

    Topics: Antineoplastic Agents; beta Catenin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Neoplasms; Organoplatinum Compounds; Organoselenium Compounds; Oxaliplatin; Paclitaxel; RNA Interference; Taxoids; Topotecan

2010
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:11

    Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan

2010
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Topotecan

2011
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
    Gynecologic oncology, 2011, Volume: 122, Issue:1

    Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome

2011
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
    Gynecologic oncology, 2011, Volume: 122, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Topotecan

2011
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy.
    Journal of translational medicine, 2011, May-25, Volume: 9

    Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; fas Receptor; Female; Histocompatibility Antigens Class I; Humans; Immunotherapy; Interleukin-18; Mice; Mice, Inbred C57BL; Neoplasms; Paclitaxel; T-Lymphocytes; Time Factors; Topotecan; Up-Regulation

2011
Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells.
    Anticancer research, 2012, Volume: 32, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cell Line, Tumor; Chromones; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Morpholines; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Topotecan

2012
The ubiquitin-conjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth.
    Oncology reports, 2012, Volume: 28, Issue:4

    Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Paclitaxel; Promoter Regions, Genetic; Reference Values; RNA, Small Interfering; Topoisomerase I Inhibitors; Topoisomerase Inhibitors; Topotecan; Ubiquitin-Conjugating Enzymes; Uterine Cervical Neoplasms

2012
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.
    BMC cancer, 2012, Aug-29, Volume: 12

    Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Blotting, Western; Carboplatin; Cell Line, Tumor; Cisplatin; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, SCID; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Xenograft Model Antitumor Assays

2012
Treatment update in small-cell lung cancer: from limited to extensive disease.
    Current treatment options in oncology, 2012, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Topotecan

2012
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan

2013
[Analysis of drug therapy of lung cancer in Hungary].
    Magyar onkologia, 2013, Volume: 57, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan

2013
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Cyclophosphamide; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Topotecan

2013
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan

2013
Development and validation of the HPLC method for simultaneous estimation of Paclitaxel and topotecan.
    Journal of chromatographic science, 2014, Volume: 52, Issue:7

    Topics: Animals; Chromatography, High Pressure Liquid; Drug Stability; Limit of Detection; Linear Models; Paclitaxel; Rats; Reproducibility of Results; Topotecan

2014
Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Movement; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Indoles; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Topotecan

2013
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Apr-15, Volume: 20, Issue:8

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays

2014
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:5

    Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Cisplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Sirolimus; Tetrahydroisoquinolines; Topotecan; Trabectedin; Tumor Cells, Cultured

2014
Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:7

    Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Diagnostic Techniques, Surgical; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Taxoids; Topotecan

2014
Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?
    Gynecologic oncology, 2015, Volume: 136, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Decision Support Techniques; Female; Humans; Models, Economic; Paclitaxel; Topotecan; United States; Uterine Cervical Neoplasms

2015
Poly(d,l-lactide-co-glycolide)-chitosan composite particles for the treatment of lung cancer.
    International journal of nanomedicine, 2015, Volume: 10

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chitosan; Drug Carriers; Drug Synergism; Humans; Lactic Acid; Lung Neoplasms; Nanocomposites; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Topotecan

2015
Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer.
    Drug development and industrial pharmacy, 2016, Volume: 42, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Blood Cells; Calorimetry, Differential Scanning; Cell Line, Tumor; Drug Combinations; Drug Liberation; Drug Synergism; Female; Folic Acid; Humans; Liposomes; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Topoisomerase I Inhibitors; Topotecan

2016
Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2015, Volume: 74

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Colorectal Neoplasms; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Glycosylation; Humans; Ovarian Neoplasms; Paclitaxel; Phenotype; Topotecan; Tunicamycin

2015
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
    Gynecologic oncology, 2015, Volume: 139, Issue:2

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan

2015
Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report.
    BMC cancer, 2015, Oct-17, Volume: 15

    Topics: Cisplatin; Female; Humans; Middle Aged; Paclitaxel; Seizures; Status Epilepticus; Topotecan; Uterine Cervical Neoplasms

2015
Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease.
    Anticancer research, 2015, Volume: 35, Issue:11

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan

2015
Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:12

    Topics: Administration, Metronomic; Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Topotecan; Xenograft Model Antitumor Assays

2015
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
    Gynecologic oncology, 2016, Volume: 140, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Treatment Outcome; Young Adult

2016
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix.
    Gynecologic oncology, 2017, Volume: 144, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Young Adult

2017
    Bulletin du cancer, 2017, Volume: 104 Suppl 1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Topotecan

2017
ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.
    Medicine, 2017, Volume: 96, Issue:51

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma; Cisplatin; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pelvic Neoplasms; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms

2017
Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.
    Scientific reports, 2018, 06-12, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Evaluation, Preclinical; Folic Acid; Humans; Mice, Nude; Neoplasms; Oligopeptides; Paclitaxel; Pipecolic Acids; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays

2018
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.
    European journal of gynaecological oncology, 2017, Volume: 38, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan

2017
The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines.
    International journal of molecular sciences, 2018, Sep-25, Volume: 19, Issue:10

    Topics: Antineoplastic Agents, Phytogenic; Calcium-Binding Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Matrix Gla Protein; Ovarian Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topotecan

2018
Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
    Gynecologic oncology, 2019, Volume: 152, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Polyethylene Glycols; Topotecan

2019
The clinical conundrum of managing relapsed small cell lung cancer.
    Cancer, 2019, 04-01, Volume: 125, Issue:7

    Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan

2019
Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development.
    International journal of molecular sciences, 2018, Dec-23, Volume: 20, Issue:1

    Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Cell Line, Tumor; Collagen Type I; Collagen Type III; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Humans; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Primary Cell Culture; Protein-Lysine 6-Oxidase; Retinal Dehydrogenase; Topotecan

2018
Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer.
    Anticancer research, 2019, Volume: 39, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Republic of Korea; Topotecan

2019
Structure-Activity Relationships of Cytotoxic Lactones as Inhibitors and Mechanisms of Action.
    Current drug discovery technologies, 2020, Volume: 17, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Drug Design; Etoposide; Humans; Lactones; Ligands; Molecular Docking Simulation; Neoplasms; Paclitaxel; Sesquiterpenes; Structural Homology, Protein; Structure-Activity Relationship; Topotecan; Tubulin; Tubulin Modulators

2020
Structure Based Drug Design and Molecular Docking Studies of Anticancer Molecules Paclitaxel, Etoposide and Topotecan using Novel Ligands.
    Current drug discovery technologies, 2020, Volume: 17, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Drug Design; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lactones; Ligands; Molecular Docking Simulation; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-myb; Sesquiterpenes; Structure-Activity Relationship; Topotecan

2020
Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years.
    Gynecologic oncology, 2019, Volume: 153, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Drug Administration Schedule; Epirubicin; Female; Humans; Medication Adherence; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Topotecan; Tumor Burden; Young Adult

2019
HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
    Molecular cancer research : MCR, 2019, Volume: 17, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cisplatin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Ovarian Neoplasms; Paclitaxel; RNA, Small Interfering; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2019
Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols.
    Acta pharmaceutica (Zagreb, Croatia), 2019, Mar-01, Volume: 69, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Topotecan; Treatment Outcome; Young Adult

2019
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer.
    European journal of cancer care, 2020, Volume: 29, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Comorbidity; Cyclophosphamide; Deprescriptions; Docetaxel; Doxorubicin; Drug Tapering; Etoposide; Female; Functional Status; Humans; Lung Neoplasms; Male; Middle Aged; Netherlands; Paclitaxel; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan

2020
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2020, Volume: 30, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan

2020
Autophagy inhibition and microRNA‑199a‑5p upregulation in paclitaxel‑resistant A549/T lung cancer cells.
    Oncology reports, 2021, Volume: 46, Issue:1

    Topics: A549 Cells; Autophagy; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; MicroRNAs; Oxaliplatin; Paclitaxel; Sequestosome-1 Protein; Topotecan; Up-Regulation; Vinorelbine

2021
Synchronizing the release rates of topotecan and paclitaxel from a self-eroding crosslinked chitosan - PLGA platform.
    International journal of pharmaceutics, 2022, Jul-25, Volume: 623

    Topics: Calcium Chloride; Chitosan; Hydrogels; Paclitaxel; Topotecan; Water

2022
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
    Journal of pharmaceutical and biomedical analysis, 2022, Nov-30, Volume: 221

    Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water

2022
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
    American journal of obstetrics and gynecology, 2023, Volume: 228, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cervix Uteri; Cisplatin; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Registries; Retrospective Studies; Topotecan; Uterine Cervical Neoplasms

2023